CooperCompanies Elects Maria Rivas, MD to Board of Directors

Rhea-AI Summary

CooperCompanies has elected Dr. Maria Rivas as an independent director, effective July 1, 2021. Dr. Rivas brings extensive experience in fertility, medical affairs, and product development from her role at Merck KGaA. Al White, CEO, expressed confidence in her contributions as the company seeks growth. The Board now consists of eight directors, with six being independent, highlighting a strengthened governance structure. This follows recent appointments and changes in leadership aimed at enhancing strategic oversight, as part of Cooper's ongoing commitment to improving corporate governance.

Positive

• Dr. Maria Rivas brings a wealth of experience in fertility and medical affairs, enhancing the Board's expertise.
• The addition of Dr. Rivas strengthens the Board's independence with six out of eight directors being independent.
• Recent leadership changes indicate a proactive approach to corporate governance and strategic growth.

Negative

• None.

SAN RAMON, Calif., May 12, 2021 (GLOBE NEWSWIRE) -- CooperCompanies (NYSE: COO) announced today that its Board of Directors has elected Dr. Maria Rivas as an independent director, effective July 1, 2021.

“We are pleased to welcome Maria to our Board of Directors,” said Al White, President and CEO. “Maria brings a very valuable perspective with her background in fertility, medical affairs, product development, and global regulatory. We look forward to her advice and contributions as CooperCompanies continues to grow.”

Dr. Rivas currently serves as Chief Medical Officer and Senior Vice President for the healthcare business of Merck KGaA, Darmstadt, Germany (which operates as EMD Serono in the US and Canada) where she leads the Global Pharmacovigilance, Medical Affairs and Evidence and Value Development (HEOR) teams in over 90 countries.

Prior to that, Dr. Rivas served as Senior Vice President of Global Medical Affairs at Merck & Co (MSD), as Vice President of Global Medical Affairs at Abbvie, as Vice President of Oncology, General Medicine and Diagnostic Imaging Medical Affairs at Bayer Healthcare, and in various roles at Eli Lilly including Head of US Women’s Health Medical Affairs. Before joining Eli Lilly, Dr. Rivas was in private practice as an endocrinologist in Puerto Rico.

Born in Cuba, Dr. Rivas grew up in Puerto Rico and still has many family, friends and professional connections there. In 2020, she was named among the Top 100 Most Influential Latinas by Latino Leaders Magazine.

Cooper’s Board of Directors has welcomed several new directors and leaders in recent months. In November 2020, Teresa S. Madden was elected to the Board as an independent director. In March, Robert S. Weiss was elected Chairman of the Board, and William A. Kozy was elected Vice Chairman and Lead Director replacing A. Thomas Bender and Allan E. Rubenstein, M.D., respectively, who retired after many years of service.

With the addition of Dr. Rivas, the Board will be comprised of eight directors, six of whom are independent. Cooper’s Board members are:

1. Robert S. Weiss, Chairman of the Board
2. William (Bill) A. Kozy, Vice Chairman and Lead Director
3. Colleen E. Jay, Director
4. Jody S. Lindell, Director
5. Teresa S. Madden, Director
6. Gary S. Petersmeyer, Director
7. Dr. Maria Rivas, Director (effective July 1, 2021)
8. Albert G. White III, President & Chief Executive Officer, CooperCompanies

About CooperCompanies
CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE: COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, CA, Cooper has a workforce of more than 12,000 with products sold in over 100 countries. For more information, please visit www.coopercos.com.

Contact:
Kim Duncan
Vice President, Investor Relations and Risk Management
925-460-3663
ir@cooperco.com

FAQ

Who is the new director elected by CooperCompanies?

Dr. Maria Rivas has been elected as an independent director of CooperCompanies.

What experience does Dr. Maria Rivas bring to CooperCompanies?

Dr. Rivas has significant experience in fertility, medical affairs, and product development, previously serving at Merck KGaA and other major pharmaceutical companies.

When will Dr. Maria Rivas officially join the Board of CooperCompanies?

Dr. Maria Rivas will officially join the Board on July 1, 2021.

How many independent directors are on CooperCompanies' Board after this appointment?

After Dr. Rivas' appointment, there are six independent directors on CooperCompanies' Board.

What is the significance of the new appointments in the Board of CooperCompanies?

The new appointments, including that of Dr. Rivas, represent a strategic effort to enhance governance and provide diverse perspectives as CooperCompanies continues to grow.